The landmark symposium, A Decade of the Tobacco Control Act Progress, Setbacks, and the Future of Tobacco Control, organized by the Public Health Law Center and held in conjunction with the 2019 National Conference on Tobacco or Health, assessed the first 10 years of federal tobacco regulation. In this introduction to the symposium, the Public Health Law Center's executive director provides the context for insights by prominent experts from government, health organizations, and academia, acknowledging the mixed record of U.S. Food and Drug Administration (FDA) regulation to date and suggesting that the agency's ultimate success or failure will be determined by the answers to three fundamental, but still unresolved, questions What is the true goal of federal regulation? How boldly or cautiously will the FDA approach that goal? And who will the agency serve? The answers to those questions, he argues, will determine the prospects for progress in controlling the nation's leading cause of preventable death.After a decade of fits and starts in regulating commercial tobacco products, the U.S. Food and Drug Administration (FDA) has built the infrastructure needed for robust tobacco product regulation. This article lays out a vision for the FDA in its second decade of tobacco product regulation. To realize the promise of the Family Smoking Prevention and Tobacco Control Act, the FDA must move quickly to adopt high-impact tobacco product regulation, define and operationalize the public health standard in a way that advances health equity, and bring all of its authority and resources to bear to reduce health disparities. In addition, the agency must engage more productively with states to reduce and eliminate tobacco use.In the 10 years that the U.S. Food and Drug Administration (FDA) has been regulating tobacco products, the agency has been plagued with setbacks, some of its own making, and some the result of outside forces. What has been consistently true is that the public health community has not had as much of a voice as it should have until public health groups began filing lawsuits against the FDA. This article examines four areas of FDA regulation over the last decade in an attempt to qualitatively describe the work of the Center for Tobacco Products and identify opportunities for public health groups to have greater advocacy success in the future.Introduction Tobacco control policies have helped to reduce the health, social, and economic burden of commercial tobacco use worldwide. Little is known about the long-term impact of regulatory policies and functioning bodies that make recommendations to inform policies. The Tobacco Products Scientific Advisory Committee (TPSAC) of the U.S. Food and Drug Administration (FDA) was formed in 2009 to evaluate the safety, health, and dependence of tobacco products and provide related advice and recommendations to the FDA and the Secretary of Health and Human Services. This article describes the first 10 years of the TPSAC activities and reflects on the impact of their service on regulatory actions.Methods We reviewed public documents from the 2010-2019 TPSAC meetings to examine the purposes, TPSAC decisions, public health participation in meetings, and concordance of the TPSAC recommendations with regulatory actions. Meeting agendas, transcripts, public testimony, and presentations were reviewed to obtain this inftobacco use in the United States.This article describes the impact of the 2009 Family Smoking and Prevention Tobacco Control Act (TCA) on local tobacco control through the lens of New York City's experience during the first 10 years after the TCA was enacted, highlighting one meaningful change and an opportunity that has failed to materialize. Much of the analysis regarding the TCA highlights the U.S. Food and Drug Administration's (FDA) new powers and the TCA's impact on a national level. However, the TCA also opened up opportunities for local governments to pursue sound tobacco control policies that previously seemed fraught with high legal risk. This article focuses on two aspects of the TCA. First, the TCA weakened one of the tobacco industry's most reliable litigation weapons-preemption. Second, the TCA authorized the FDA to combat the illicit trade of tobacco products. Despite clear language in the TCA, the FDA has not signaled an inclination to take action regarding illicit trade in the context of tobacco tax evasion.Efforts to reduce the risk of opioid misuse are often focused on reducing unnecessary prescriptions for opioid medications or reducing the dose prescribed; however, not all misuse occurs in individuals with a personal prescription. This study examined trends in the proportion of adolescents and young adults (AYAs) who had an opioid-related problem (ORP) and who also had a personal opioid prescription drug claim or had a family member with an opioid prescription drug claim prior to the ORP diagnosis. A retrospective cohort design was used to analyze longitudinal claims data. We identified individuals aged 12 to 25?years who had a newly diagnosed ORP in the years 2006 to 2014. Trends over time in personal or family opioid prescription drug claims within 1 year prior to ORP diagnosis were examined. We identified 53,560 AYAs with an ORP diagnosis. Over the entire study period, 40% of AYAs with an ORP diagnosis had a personal opioid prescription in the year prior to diagnosis, and 48% had a family member wctly, although prescriptions to family members may still remain a point of access.The opioid use disorder (OUD) epidemic is a national public health crisis. Access to effective treatment with buprenorphine is limited, in part because few physicians are trained to prescribe it. Little is known about how post-graduate trainees learn to prescribe buprenorphine or how to optimally train them to prescribe. https://www.selleckchem.com/products/S31-201.html We therefore aimed to explore the experiences and attitudes of residents learning to prescribe buprenorphine within two primary care-based opioid treatment models. We performed semi-structured interviews with second- and third-year internal medicine residents at an urban academic residency program. Participating residents practiced in clinics providing buprenorphine care using either a nurse care manager model or a provider-centric model. Subjects were sampled purposively to ensure that a diversity of perspectives were included. Interviews were conducted until theoretical saturation was reached and were analyzed using principles of thematic analysis. The research team developed a consensus code list.